Famciclovir

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Wednesday, February 28, 2024
Celecoxib, Fibromyalgia, Letter, Famciclovir, FDA, Management, Food, Conditional sentence, Valaciclovir, Therapy, Research, Pharmaceutical industry

ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.

Key Points: 
  • ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.
  • On behalf of the Virios directors and the executive team, we would like to provide a corporate progress report on several key topics as we proceed through the first quarter of 2024.
  • Approval of this proposal does not commit the Company to the execution of a reverse stock split.
  • The Virios team remains committed to delivering on the promise of combination antiviral therapy to address a multitude of serious health issues and illnesses.

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Thursday, May 25, 2023
Celecoxib, Famciclovir, Fibromyalgia, Toxicology, FDA, Therapy, Letter, Auction

ATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Key Points: 
  • ATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
  • Below are some recent key developments in the business, including the Company regaining compliance with the minimum bid price requirement.
  • On May 24th, 2023, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because Virios Therapeutic’s (“VIRI”) shares had a closing bid price at or above $1.00 per share for 10 consecutive business days, VIRI stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
  • The Company submitted final toxicology reports as per FDA’s request as part of their overall review of the Phase 3 proposal.

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Retrieved on: 
Monday, May 15, 2023
Celecoxib, Famciclovir, Patient, Toxicology, Fibromyalgia, Food and Drug Administration, Conditional sentence, FDA, Therapy, Food, Pharmaceutical industry

ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it has submitted final toxicology reports as per Food & Drug Administration (“FDA”) request as part of their overall review of the Company’s Phase 3 proposal.

Key Points: 
  • ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it has submitted final toxicology reports as per Food & Drug Administration (“FDA”) request as part of their overall review of the Company’s Phase 3 proposal.
  • Based on data from its recently completed FORTRESS Phase 2b trial, the Company proposed a Phase 3 development program targeting community-based FM patients, who have not participated in prior FM trials.
  • “We are pleased to report that we have submitted the final toxicology program results in support of our proposal to advance IMC-1 to Phase 3 development,” said Greg Duncan, Chairman and CEO of Virios Therapeutics.
  • “We will report material FDA feedback on our Phase 3 proposal promptly, as we receive it.”

Virios Therapeutics Announces First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Partnership, Celecoxib, Research, Famciclovir, Patient, Toxicology, Fibromyalgia, Conditional sentence, FDA, Therapy, Valaciclovir, Pharmaceutical industry

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the first quarter ended March 31, 2023.
  • Research and development expenses for the first quarter of 2023 were $0.5 million, compared to $2.8 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $1.1 million, compared to $1.2 million for the first quarter of 2022.
  • As of March 31, 2023, Virios Therapeutics’ cash totaled $5.3 million.

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Retrieved on: 
Monday, April 24, 2023
FM, Anesthesiology, Celecoxib, Famciclovir, Addiction medicine, Patient, Toxicology, Fibromyalgia, Conditional sentence, FDA, Therapy, Pharmaceutical industry

ATLANTA, April 24, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced a program summary based on initial feedback from the U.S. Food & Drug Administration (“FDA”) on its Phase 3 FM program proposal featuring its lead development candidate IMC-1. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted fibromyalgia disease symptoms. This feedback was provided following a guidance meeting between the Anesthesiology, Addiction Medicine and Pain Medicine division of FDA and the Company in March 2023.

Key Points: 
  • This feedback was provided following a guidance meeting between the Anesthesiology, Addiction Medicine and Pain Medicine division of FDA and the Company in March 2023.
  • Based on data from the recently completed FORTRESS Phase 2b trial, the Company proposed a Phase 3 development program targeting community-based FM patients, who have not participated in prior FM trials.
  • Initial FDA feedback was that the Company’s Phase 3 proposal is acceptable, subject to review of the final results from its recently completed chronic toxicology program.
  • An updated IMC-1 Phase 3 program proposal, responsive to FDA guidance, will also be provided once FDA completes its review of the chronic toxicology reports.

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Retrieved on: 
Tuesday, November 29, 2022
Health, FDA, COVID-19, General Health, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Real estate, BHC, Diagnosis, Metal, Attention, Agriculture, Conditional sentence, Long COVID, Center of excellence, Pain, Indian stock exchange, Therapy, Valaciclovir, Fibromyalgia, Sleep, Fatigue, Perpetual Real Estate Services, Inc. v. Michaelson Properties, Inc., Financial services, FM, Anxiety, Consumer, Planet, Publishing, News, Functional somatic syndrome, Short bowel syndrome, Celecoxib, Famciclovir, PASC, Chronic fatigue syndrome, FDA, Simplex, Pharmaceutical industry, Health care, Mining

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Key Points: 
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • Planet MicroCap is a global multimedia and publishing financial news investor portal specifically focused on covering the MicroCap market by providing news, insights, education tools and expert commentary.
  • The Planet MicroCap Showcase will take place virtually, featuring 50+ companies, buy-side and sell-side analysts, wealth managers, institutional investors, family offices, hedge fund managers, retail investors and others.
  • Sectors Participating: Agriculture, Biopharma, Consumer, Energy, Financial Services, Healthcare, Industrials, Materials, Metals and Mining, Real Estate, Services, and Technology.

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
COVID-19, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, FDA, Center of excellence, Communication, Advertising, Clinical trial, Anxiety, Grammatical mood, Valaciclovir, Simplex, Environment, Fibromyalgia, Functional somatic syndrome, Drug development, Therapy, Database, Short bowel syndrome, Famciclovir, Patient, Conference, Attention, PASC, Doctor of Philosophy, Fatigue, Vaccination, COVID, FM, Research, Depression, Chronic fatigue syndrome, Celecoxib, Sleep, Pain, Conditional sentence, COVID-19, Diagnosis, COVID-19 testing, BHC, Webcast, Pharmaceutical industry, MD

Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.

Key Points: 
  • Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.
  • General and administrative expenses for the third quarter ended September 30, 2022 were $0.9 million, compared to $1.1 million for the third quarter ended September 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on November 14, 2022, at 8:30 a.m.
  • ET to discuss the Companys financial results and provide a corporate update.

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Company, Center of excellence, Fatigue, Simplex, Fibromyalgia, Celecoxib, FDA, Investor, Webcast, Functional somatic syndrome, PASC, Short bowel syndrome, COVID-19, Therapy, Nasdaq, Attention, Famciclovir, Sleep, Conditional sentence, Anxiety, FM, Valaciclovir, Center, Chronic fatigue syndrome, Diagnosis, Pain, BHC, Pharmaceutical industry

Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m.

Key Points: 
  • Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m.
  • ET to discuss the results and provide a corporate update.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Virios Therapeutics, Inc. Announces Closing of Public Offering

Retrieved on: 
Thursday, September 22, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Celecoxib, Conditional sentence, ThinkEquity, COVID-19, Short bowel syndrome, State Street, Sale, S-3, U.S. Securities and Exchange Commission, Company, Fibromyalgia, Functional somatic syndrome, Therapy, Valaciclovir, Forward-looking statement, Famciclovir, Attention, Chronic fatigue syndrome, Pain, SEC filing, Annual report, Nasdaq, Anxiety, Private Securities Litigation Reform Act, Telephone, Sleep, Form, Security (finance), Prospectus, SEC, Simplex, Fatigue, FM, Vaccine

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.
  • The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.
  • ThinkEquity acted as sole book-running manager for the offering.
  • The final prospectus supplement relating to the offering was filed with the SEC and is available on the SECs website at www.sec.gov .

Virios Therapeutics, Inc. Announces Pricing of Public Offering

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Celecoxib, Conditional sentence, ThinkEquity, COVID-19, Short bowel syndrome, State Street, Sale, S-3, U.S. Securities and Exchange Commission, Company, Fibromyalgia, Functional somatic syndrome, Therapy, Valaciclovir, Forward-looking statement, Famciclovir, Attention, Chronic fatigue syndrome, Pain, SEC filing, Annual report, Nasdaq, Anxiety, Private Securities Litigation Reform Act, Telephone, Sleep, Form, Security (finance), Prospectus, SEC, Simplex, Fatigue, FM, Vaccine

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.
  • The offering is expected to close on September 22, 2022, subject to satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.
  • ThinkEquity is acting as sole book-running manager for the offering.